Immunis Partners with Springbok Analytics to Assess Clinical Efficacy of IMMUNA in Reversing Sarcopenia
2024年7月25日 - 11:10PM
ビジネスワイヤ(英語)
Immunis is implementing Springbok’s MRI-based
AI muscle analysis technology in its Phase 1/2a Clinical Trial to
assess the efficacy of its novel secretome therapeutic (IMMUNA) in
targeting sarcopenia.
Immunis, Inc., a clinical-stage biotech developing
groundbreaking secretome therapeutics for age and disease-related
immune dysfunction, announced today its partnership with Springbok
Analytics, a life sciences muscle analytics company. Springbok is
building a new standard in muscle health with its MRI-based AI
muscle analysis technology that is used widely throughout elite
sports, human performance and life sciences. Immunis is using
Springbok’s technology to evaluate the efficacy of its
investigational secretome therapeutic, IMMUNA, in restoring muscle
growth and function in a sarcopenic Phase 1/2a clinical trial
population.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240725463538/en/
(Graphic: Business Wire)
Sarcopenia, a condition characterized by age-related muscle
loss, is a major driver of disability in elderly adults. Muscle
atrophy is a leading contributor to falls, fractures,
hospitalization, and comorbidities, accounting for more than $40
billion in annual health care costs in the United States alone.
Sarcopenia is an inevitable symptom of aging, and yet there are no
pharmaceutical interventions to prevent or address the issue.
Immunis has developed a novel therapy using human cell-derived
secretions with hundreds of natural factors to potentially treat
complex, age-related diseases like sarcopenia. In published
pre-clinical analyses, Immunis’ novel secretome (IMMUNA) was shown
to enhance muscle regeneration, improve muscle strength, increase
metabolism, and reduce fat. Immunis is nearing the completion of
its Phase 1/2a clinical trial, which tests the safety,
tolerability, and efficacy of IMMUNA in reversing muscle atrophy in
an aged population with knee osteoarthritis.
“Springbok is essential to our analytical pipeline as we process
and critically assess the clinical trial data we are gathering in
our efforts to reverse various aspects of aging,” said Erin Curry,
Director of Medical Affairs at Immunis. “Springbok greatly enhances
the accuracy and acuity of our outcomes, allowing us to more
clearly understand how muscle and the body changes with IMMUNA over
time.”
Springbok has developed the first commercialized technology to
accurately quantify individual muscles from a rapid MRI. Its
analysis will provide precision insights into the muscle health and
overall muscle development of Immunis’ clinical trial participants,
and specifically how IMMUNA is altering tissue architecture and
function. “We are relying on Springbok to better understand the
biological efficacy of our potentially groundbreaking secretome
therapy,” says Dr. Karissa Muñoz, Sr. Scientific Communications
Manager at Immunis. “Springbok allows us to get more coverage and
resolution from each MRI scan, as well as shorter imaging table
times for trial participants, enhancing their overall
experience.”
Springbok’s lower extremity (LE) scan takes under 10 minutes of
imaging time, and its full body scan can be done in less than 40
minutes. Its flexible imaging protocol has been implemented at
hundreds of imaging centers around the world and is compatible
across all major scanner platforms. “This work with Immunis shows
yet another use case for our powerful core technology –
personalized muscle analysis from a rapid MRI,” said Scott
Magargee, Springbok CEO and Co-Founder. “We continue to improve the
efficacy of muscle-related clinical trials with our automated,
objective, precise and scalable analysis.”
The potential applications of IMMUNA as a therapy are vast and
promising. IMMUNA stands on the precipice of offering a
transformative solution for extending healthspan, improving quality
of life, and addressing the unmet needs of millions affected by
muscle atrophy.
About Immunis Inc.
Immunis is a private biotechnology company developing a novel
immunomodulatory secretome product for the various manifestations
of age and disease-related immune decline. The investigational
product line leverages Immunis’ leading-edge capabilities in
secretome technology to deliver a product of all natural, all human
immune modulators in their natural relative physiological
concentrations.
For additional information about Immunis’ Phase 1/2a clinical
trial please visit:
https://immunisbiomedical.com/clinical-trials/
About Springbok Analytics
Springbok is a life sciences muscle analytics company that
drives better health and performance outcomes.
Its technology analyzes MRI data and creates personalized 3D
visualizations of muscle health, enhancing the assessment,
treatment monitoring, research and diagnostic value of advanced
imaging. Springbok's rapid imaging sequence and AI-based analysis
reveals a complete view of musculoskeletal health, precisely
quantified individual muscle volume and quality, fat infiltration,
left-right asymmetries, as well as scar tissue, edema, and tendon
morphology.
To learn more about how Springbok is creating a better view of
health, please visit: www.springbokanalytics.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240725463538/en/
contact@immunisbiomedical.com